Skip to content

EBIT at other companies

Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-$103.61M-38.3%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Eli Lilly logo
Eli LillyLLY
Pfizer logo
PfizerPFE
Amgen logo
AmgenAMGN
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.25B+1,196%
Enterprise value$4.25B+1,265%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Calculated from Erasca, Inc.’s reported figures.

Plus components not separately reported this period.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s EBIT?
Erasca, Inc. (ERAS) reported EBIT of -$187.91M in Q1 2026.
How has Erasca, Inc.'s EBIT changed year-over-year?
Erasca, Inc.'s EBIT decreased by 427.4% year-over-year, from -$35.63M to -$187.91M.
What is the long-term trend for Erasca, Inc.'s EBIT?
Over 4 years (2021 to 2025), Erasca, Inc.'s EBIT has grown at a 3.1% compound annual growth rate (CAGR), from -$124.88M to -$140.91M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.